Impaired cellular immune responses in chronic renal failure: Evidence for a T cell defect  by Kurz, Peter et al.
Kidney International, Vol. 29 (1986), pp. 1209—12 14
Impaired cellular immune responses in chronic renal failure:
Evidence for a T cell defect
PETER Kuiz, HANS KOHLER, STEPHAN MEUER, THOMAS HUTTEROTH,
and KARL—HERMANN MEYER ZUM BUSCHENFELDE
1st Department of Internal Medicine, Johannes Gutenberg—University, Mainz, Federal Republic of Germany
Impaired cellular immune responses in chronic renal failure: Evidence
for a T cell defect. Cellular immune responses in vitro were studied in 24
patients on chronic hemodialysis and 16 healthy volunteers with normal
kidney function. Patients on maintenance hemodialysis had lymphope-
nia with diminished numbers of both T4 and 18* T-lymphocytes. The
14/18 ratios were within the normal range. Peripheral blood lympho-
cytes (PBL) showed a diminished proliferative response upon stimula-
tion with concanavalin A, phytohemagglutinin and pokeweed mitogen.
When cell surface antigens were used for stimulation (mixed lympho-
cyte culture) uremic lymphocytes also showed a lower proliferation
rate. Although without statistical conformation, there was a tendency
by uremic PBL to produce less lL-2 as compared to healthy controls.
Moreover, in a PWM driven system, peripheral blood lymphocytes
from uremics produced significantly less lgG than PBL from normals.
These results support the notion that a profound defect in lymphocyte
function accounts at least, in part, for the observed immunodeficiency
of uremic patients.
There is a general agreement on clinical grounds that patients
on maintenance dialysis have an impaired immune response
(that is, impaired response to vaccines, reduced homograft
rejection, diminished reaction in skin tests) [1—6]. Attempts to
evaluate this type of secondary immunodeficiency in vitro have
revealed multiple defects both at the humoral and the cellular
level. With regard to the former, subnormal concentrations of
serum immunoglobulins and complement components were
reported [7]. In addition, plasma of uremic patients may contain
inhibitory activities influencing lymphocyte responses in vitro
[8, 91. Moreover, parameters of granulocyte function such as
adherence, phagocytosis and chemotaxis appear to be abnormal
[10]. The number of circulating lymphocytes in uremic patients
is generally reduced with a normal ratio of T4 (helper cells) to
T8 (suppressor cells). However, studies on lymphocyte func-
tion have yielded controversial results [11, 12]. Thus, whereas
some authors found normal proliferative responses to lectins
and alloantigens, others reported reduced [13, 14] or even
enhanced in vitro proliferation to such stimuli.
The present study was undertaken to evaluate in greater
detail lymphocyte functions of patients on chronic hemodialysis
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as compared to healthy controls. To this end we have examined
proliferative T cell responses to mitogens and alloantigens.
In addition, the production of Interleukin-2 following
PHA—stimulation was used to evaluate a critical contribution of
T cells in the immune response [15]. Finally, to measure B cell
differentiation as a result of T-B cell collaboration, IgG secre-
tion by PBL in response to PWM triggering was investigated
[16]. The data reported demonstrate diminished activities of
circulating lymphocytes in all systems employed. Perhaps more
importantly, this seems to be unrelated to inhibitory plasma
activities and therefore supports the notion that defects in
cellular function or, alternatively, pertubation of critical minor
lymphocyte subpopulations may contribute to abnormal im-
mune responses in the uremic state.
Methods
Patients. Twenty—four patients receiving hemodialysis for
chronic renal failure were studied. Fifteen patients were male,
nine patients female. The age ranged from 27 to 77 years with a
mean age of 53.3 years. Patients had been receiving dialysis for
one to 13 years with a mean of 4.8 years. None of the patients
received drugs known to influence the immune response. Pa-
tients were dialyzed with various types of dialyzers (Lundia 10
SN, Gambro, Lund, Sweden; Hemoflow C 1,0, Fresenius, Bad
Homburg, FRG; PPD 1,9, Cobe Lakewood, USA) for a mean
duration of 4.5 hr (range 4 to 5 hr).
Controls. Sixteen apparently healthy controls (laboratory
personnel and patients from the hypertensive outpatient clinic
with normal kidney function) were studied (Table 1).
Isolation of cells
Heparinized blood drawn before the start of hemodialysis
was subjected to density gradient centrifugation using Ficoll
Paque (Pharmacia Fine Chemical, Uppsala, Sweden). Interphas-
es were washed three times in RPMI 1640 containing 2% fetal
calf serum (FCS). Cells were resuspended in 1 muter culture
medium and counted. Equal aliquots were taken for the blast
transformation studies in FCS and uremic serum. PBL were
adjusted to a final concentration of 1 x 106 cells/mliter in RPMI
1640 containing 10% FCS or 10% uremic serum supplemented
with penicillin—streptomycin. Mononuclear cells were cultured
in triplicate in multiple round bottom microtiter plates (Costar,
Cat. No. 3799, Cambridge, Massachusetts, USA) for three days
at 37°C in a humidified 5% carbon dioxide atmosphere. l0 PBL
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in a total volume of 200 1diter were stimulated with
concanavalin A (Con A) 12.5 g/mliter, phytohemagglutinin
(PHA) 5 g/mliter or pokeweed mitogen at a final dilution of
1:100. In a one way mixed lymphocyte culture (MLC), iO PBL
were incubated with iO irradiated (5000 rad) allogeneic B-cells
(an Epstein Barr virus transformed human lymphoblastoid
B-cell line). Sixteen hr prior to termination of the cultures, wells
were individually pulsed with I pCi of 3H-Thymidine (3H-TdR)
(New England Nuclear, Boston, Massachusetts, USA). Cul-
tures were harvested on filter papers using a Titertek cell
harvester. Filters were dried and counted in a liquid scintillation
spectrometer (Packard). Results are expressed as Stimulation
Index (SI) obtained by dividing cpm 3H-TdR uptake of stimu-
lated cultures by medium controls (SD < 20%).
SI = cpm of stimulated PBL/cpm medium control.
Statistical significance was determined by Wilcoxon rank
sum test.
Characterization of lymphocyte subpopula lion with
monoc/onal antibodies
Human mononuclear blood cells were isolated from
hemodialysis patients and healthy volunteer donors by Ficoll
Hypaque density gradient centrifugation. Mononuclear cells
were washed twice in culture medium containing 5% FCS. 106
PBL were incubated with monoclonal antibody [17, 181 in a final
volume of 50 piiter at 4°C for 1 hr. A monoclonal anti-T3
antibody (anti-T3A, mature T cells) in ascites form was used at
a 1:300 dilution. Anti-T4 (helper cells) and anti-T8 (suppressor
cells) were purchased from Coulter Electronics and used at an
optimal concentration. Peripheral blood mononuclear cells
from the same patients were also analyzed for their reactivity
with anti-B I monoclonal antibodies (Coulter Electronics,
Krefeld, FRG). After one hr, cells were washed twice and then
incubated with 200 piiter of a 1:20 dilution of rabbit—anti-mouse
IgG-FITC (Dako, Copenhagen, Denmark) for 30 mm at 4°C,
centrifuged and washed three times. Mouse NS-l ascites and
G/M FITC served as negative controls (background staining).
Cells were then analyzed on a fluorescent microscope (Leitz,
Wetzlar, FRG) counting at least 100 cells/sample.
In vitro production of lgG
IO unfractionated PBL were cultured in triplicate in round
bottom microtiter culture plates at 37°C, 5% CO2 in humidified
atmosphere for seven days. Final culture medium was RPM!
1640 supplemented with 1% penicillin—streptomycin, 200 mM
L-glutamin and 10% FCS. Each well contained a total volume
of 200 pliter. PBL were stimulated with PWM at a final dilution
of 1:100 (previously tested to be optimal). After seven days
lymphocytes were pelleted and supernatants harvested and
stored at — 70°C.
Elisa for IgG
To measure the amount of IgG produced by PBL following
PWM stimulation, culture supernatants were assayed in 96
well, flexible polyvinyl microtiter plates (Dynatech Laborato-
ries, Cat No. 1-200-29, Virginia, USA). Wells had been previ-
ously coated with rabbit—anti-human IgG (Behring, Marburg,
FRG) (100 itliter, 1:1000 dilution) for 16 hr at room temperature.
Unbound antibody was removed from the plates by washing
several times with PBS. Subsequently, plates were blocked
with 1% bovine serum albumin (BSA) in PBS for 1 hr at 20°C.
Wells were next washed twice with PBS (0.01 M, pH 7.5 and
0.05% Tween 20). One hundred piiter of culture supernatant at
1:5 and 1:50 dilutions in PBS were added and incubated
overnight at room temperature. Wells were washed three times
with PBS/Tween and then incubated with 200 pliter rabbit—anti-
human IgG conjugated with alkaline phosphatase (Behring) for
four hr at 37°C. After three washing cycles with PBS/Tween,
200 iliter of substrate (p-NPP, Sigma, St. Louis, Missouri,
USA) was added to each well (5 mg p-NPP diluted in 5 mliter
NaHCO3 0.05 M with 0.02% MgCl2, pH 9.6) and incubated for
three hours at 37°C. The enzymatic reaction was stopped with
50 diter NaOH and OD measured at 450 nm wave length
(Titertek Multiscan). Standard curves were set up for each plate
showing a linear course from 10 ng/mliter to 500 ng/mliter.
Production of IL-2 containing culture supernatants
PBLwere cultured at 2.5 x 106 cells/mliter in culture medium
containing 2% FCS, 1% penicillin—streptomycin, 200 mi'i L-
glutamin and phytohemagglutinin (5 g/mliter). Cells were
incubated for two hr at 37°C in humidified atmosphere, then
washed three times with culture medium to remove excess
PHA, and resuspended in culture medium as mentioned above.
After 48 hr in culture, cells were pelleted by centrifugation.
Supernatants were collected, filtered through 0.45 m Millex
filters (Millipore) and stored at —20°C.
Determination of IL-2 activity
T lymphoblasts were produced by stimulation of PBL with
phytohemagglutinin (0.5 g/mliter) for five days in culture
medium containing 10% FCS supplemented as above. After five
days of incubation, cells were harvested, washed three times,
and used as IL-2 responder cells. IL-2 concentration of culture
Table 1. Patient characteristics
Blood
Pat. Dialysis transfusions
no. Sex Age Primary kidney disease years last 6 months
I f 48 glomerulonephritis 9 no
2 m 73 toxic renal failure I yes
3 f 38 diabetic nephropathy I no4 m 35 glomerulonephritis 10 no
5 m 28 Alport's syndrome 7 no
6 f 62 chronic pyelonephritis 3 no
7 f 61 diabetic nephropathy 2 no
8 m 63 nephrosclerosis I no9 m 56 hydronephrosis I no10 m 50 nephrosclerosis 4 no
II m 27 IgA nephropathy 2 no
12 f 72 diabetic nephropathy 7 no
13 f 43 glomerulonephritis 13 no
14 m 70 polycystic kidney disease 4 yes
15 f 51 chronic pyelonephritis 12 no
16 m 67 polycystic kidney disease 7 no
17 m 38 diabetic nephropathy 4 no
18 m 77 analgesic nephropathy 3 no
19 m 63 nephrosclerosis 2 yes
20 f 29 chronic pyelonephritis 8 no
21 m 68 glomerulonephritis 5 no22 m 49 diabetic nephropathy I no
23 m 55 diabetic nephropathy 5 no
24 f 57 chronic pyelonephritis 3 no
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Table 2. Proliferative responses of patient (A) and control (B)
lymphocytes following mitogenic and allogeneic stimulation
Medium
supp. with MLC
Con A
12.5 g/mIiter
PHA
5 g/mliter
PWM
1:100
A. Patient
5% FCS 8.3 1.1 12.0 1.4 37.0 3.8 12.9 2.1
5% uremic
serum 9.1 1.9 21.0 3.6 49.1 6.6 20.6 4.1
P value NS NS NS NS
B. Control
5% FCS 22.7 3.6 45.9 8.5 85.6 12.0 24.0 3.1
5% uremic
serum 12.2 2.5 20.7 2.6 57.1 7.3 28.3 3.6
P value NS NS NS NS
Results are mean SI SEM.
supernatants was determined by proliferation (3H-TdR uptake)
of 5 x io lymphoblasts/well when incubated with three serial
dilutions of culture supernatant (1:10, 1:30 and 1:100) and
compared with the activity of serial dilutions of an IL-2 stan-
dard (40 U IL-2/mliter) (recombinant IL-2, Sandoz, Vienna,
Austria). After 24 hr, cultures were pulsed with I Ci 3H-
thymidine and harvested 16 hr later on a Titertek cell harvester.
3H-TdR incorporation was measured in a Packard scintillation
spectrometer. IL-2 concentrations were calculated according to
Gillis et at [19]. The highest concentration of supernatant of
lymphocytes from patients and controls always gave the highest
3H-TdR uptake and diluted out in a dose—dependent fashion.
The most sensitive dilution to judge the difference in IL-2
production was found to be 1:30. The level of 3H-TdR uptake
mediated by the latter dilutions of the various patient derived
supernatants was then compared to the respective value of the
standard curve and the IL-2 concentration calculated.
Results
Characterization of peripheral blood lymphocyte
subpopularions
Since patients on hemodialysis have been reported to present
with low white blood cell counts, it was first necessary to
determine leukocyte as well as lymphocyte numbers of our
patient collective. The mean leukocyte count was 8020
ce1ls/diter (range 3600 to 19000). Lymphocyte counts varied
from 640 to 2070 (mean: 1460 cells/diter). Healthy volunteers
had a mean leukocyte count of 7195 cells/tliter (range 4130 to
11220). Their mean lymphocyte count was 2534 (range 1570 to
2730). To determine whether this was due to a lack of a
particular T cell subpopulation, we utilized monoclonal anti-
bodies reactive with the T4 or the T8 subpopulation of
human peripheral lymphocytes. Analysis of T cell subpopula-
tions showed a markedly decreased number of both T4 and
T8 cells. Mean absolute number of T4 lymphocytes was 802
cells/piiter vs. 1505 cells/piiter in healthy controls. Uremics had
a mean T8 cell count of 492 cells/piiter vs. 875 cells/.diter in
the control group. Thus, the mean T4/T8 ratio was within the
normal range for both groups with 1.6 in the patient group and
1.7 in the control group. The sum of T4 + plus T8 + cells added
up to the number of T3 cells in both groups. The mean number
of B1 cells was 9.5% (range 7.6% to 13.6%) for the patient
group compared to 10.1% for the control group (range 8.6% to
10.9%).
Proliferative studies: responses to mitogens and alloantigens
Unfractionated peripheral blood mononuclear cells (I0 in
200 pJiter) were treated with 12.5 j.gImliter concanavalin A, 5
gImliter phytohemagglutinin or pokeweed mitogen (final dilu-
tion 1:100). Lymphocytes were cultured in parallel in either
fetal calf serum or uremic serum (5% final concentration). The
proliferative responses observed under these experimental con-
ditions are demonstrated in Tables 2 and 3. A significantly
reduced 3H-thymidine incorporation was observed in the dial-
ysis patient group in response to Con A, PHA, and PWM when
FCS was used. A similar result was obtained when 5000 rad
irradiated Epstein Barr virus—transformed lymphocytes were
employed as stimulator cells (Table 4). When FCS was replaced
by uremic serum, PBL from controls showed lower prolifera-
tive responses when Con A, PHA and alloantigens were used.
However, this difference was not statistically significant. For
PWM there was virtually no difference between results ob-
tained in uremic or fetal calf serum (Table 2B). Furthermore,
PBL from uremic patients cultured and stimulated in medium
containing uremic serum showed an even higher proliferative
response to all mitogens and alloantigens than in the presence of
FCS (Table 2A). These results indicate that the reduced prolif-
erative responses of lymphocytes from the uremic individuals
studied here cannot be exclusively explained on the basis of
soluble inhibitory activities present in patient sera, and thus
support the view that a severe functional abnormality may exist
within the responder cell population itself.
In vitro immuno globulin production
B lymphocyte differentiation in response to PWM is known to
be T cell—dependent. Since the above proliferation data sug-
gested a defect in I cell function of uremic patients upon
polyclonal stimulation, we examined T-helper function in B-T-
cell collaboration determining IgG production of unfractionated
lymphocytes in a PWM driven system. To this end, unfraction-
ated lymphocytes were cultured in round bottom microtiter
plates and stimulated with PWM for seven days. Subsequently,
supernatants were harvested and IgG secretion determined in a
solid phase ELISA. As demonstrated in Figure 1, B lympho-
cytes from healthy volunteers secreted significantly more IgG
than did B lymphocytes from uremic patients under these
conditions. Thus, all patients except one produced less than 500
ng IgG/105 PBL.
Interleukin 2 production in vitro
Interleukin 2 (IL-2) provides an essential signal for clonal
expansion following antigen— or mitogen—activation of T lym-
phocytes. To investigate the capacity of T cells from uremic
patients to produce this lymphokine, supernatants from PHA-
stimulated unfractionated circulating lymphocytes were ob-
tained and tested for IL-2 activity on preactivated T cell blasts.
As shown in Figure 2, uremic PBL demonstrated a tendency to
produce less IL-2 (mean 6 U/mliter) under these conditions as
compared to healthy controls (mean 16 U/mliter). However,
due to the wide variations observed, this difference did not
reach statistical significance.
Table 4. Stimulation Indices (SI) of PI3L from patients and healthy
controls stimulated with lectins and allogeneic cells in culture
medium containing 5% FCS (mean SI sEM)
MLC
Con A
12.5 ig/mliter
PHA
5 g/mIiter
PWM
1:100
Patients,
N = 24 8.3 1.1 12.0 1.4 37.0 3.8 12.9 2.1
Controls,
N = 16 22.7 3.6 45.9 8.5 85.6 12.0 24.0 3.1
P value P < 0.01 P < 0.01 P < 0.05 P < 0.05
Discussion
Immunodeficiency is a well established finding in uremic
patients [20]. Defects at both the cellular and the humoral level
have been suggested to be responsible for this abnormal reac-
tivity. Given the central role of T cells in the immune response
and previous conflicting reports regarding their function in
chronic hemodialysis patients, we attempted to investigate T
lymphocyte responses in greater detail by employing various
experimental in vitro systems. This was of particular interest in
the light of recent studies which indicated that a high proportion
of uremic non-responders exists following vaccination with
hepatitis B antigen [21] and other vaccines [2, 22]. Since the
frequency of non-responders in these studies was found to be
almost 50% [21], it seems unlikely that this finding was due to a
genetic defect. Rather, a general dysfunction of peripheral T
and/or B lymphocytes may be considered to underlie this
abnormality of protective antibody formation.
In line with previous reports, the present data demonstrate
that a pronounced lymphopenia exists in patients on chronic
hemodialysis [23]. This was, however, not due to an alteration
in the proportion of the two major human immunoregulatory T
cell subsets, T4 and T8, since the T4/T8 ratios of uremic
patients were found to be within the normal range [241. Al-
though lymphopenia may be in part responsible for the ob-
served immunodeficiency, profound abnormalities in T cell
function were found to exist also. Thus, when equal numbers of
T cells from hemodialysis patients and controls were investi-
gated for proliferative responses to mitogens (Con A, PHA,
PWM) and alloantigens, it was obvious that PBL from uremic
individuals were much less reactive [Table 4, 13]. To exclude
Stimulus
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Table 3. In vitro response of PBL of four representative patients and two healthy control individuals
Serum Pat. I Pat. 2 Pat. 3 Pat. 4 Con. I Con. 2
Medium FCS 378* 166 197 461 278 321
US 276 146 140 535 280 227
PHA FCS
US
9722
7801
7470
5239
12287
12961
17148
15721
21317
19616
18531
16157
PWM FCS
US
5056
7197
1351
3298
3130
5803
10139
16942
9921
11616
6041
9194
ConA FCS
US
2055
4566
3026
2470
1167
5813
5198
8604
4775
7686
14901
13017
MLC FCS
US
8903
3374
4434
3169
2620
3215
8303
4258
10982
4887
l6185
9875
* cpm 3H-TdR uptake (means of triplicate values; SD <20%).
Abbreviations are: FCS, fetal calf serum; US, uremic serum.
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Fig. 1. lgG concentration of supernazants of PBL from patients and
healthy controls after stimulation with PWM. 1 x l0 unfractionated
PBL were stimulated with PWM (l:lOO) for seven days. Results
represent the mean of triplicate determinations. Symbol (0) is mean
value SEM.
the possibility that lymphocytes of uremics proliferated less
because of a shorter half life in vitro, the present results were
expressed as stimulation indices rather than absolute counts of
3H.TdR uptake. Since it was reported in the past that uremia
may be associated with the existence of inhibitory serum
S
z.t
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Patients Controls
Fig. 2. IL-2 production in vitro of 2.5 x 106 PBL following stimulation
with PHA. IL-2 activity of supematants were compared with an IL-2
standard (recombinant IL-2, Sandoz). The mean of triplicate determi-
nations is given for each individual tested. Symbols (o) is mean value
SEM.
factors [8, 25], T cell responses were also investigated in the
presence of pooled sera obtained from our patient collective.
These patients had been on chronic hemodialysis for up to 12
years and should, if the above were the case, contain consid-
erable concentrations of blocking activities. However, when
proliferative responses by PBL obtained from normal donors
were investigated in the presence of uremic serum vs. FCS,
only a slight and insignificant difference was obtained when Con
A, PHA or alloantigens were employed as stimuli. It should be
noted that no difference was observed when PWM was used for
triggering and, perhaps more importantly, uremic PBL prolif-
erated even stronger in the presence of uremic sera than in
culture medium supplemented with FCS. The reasons for this
finding are not known at the present time but require further
investigation. These data provide strong support for the notion
that the abnormal T cell proliferation of uremic individuals is
mainly due to a defect within the T cell population itself [26]
rather than to blocking serum factors [25, 9]. This conclusion is
further supported by our own present findings which demon-
strate a tendency for reduced production of Interleukin-2 upon
PHA stimulation of uremic PBLs vs. healthy controls. Al-
though not shown, this was also true when alloantigens or
Phorbole myristate acetate (PMA) were employed to trigger
IL-2 release. Whether this is due to a generally lower amount of
IL-2 produced by all lymphocytes, or alternatively, a lower
fraction of IL-2 producers within the T cell population of
hemodialysis patients, remains to be determined. Limiting
dilution analysis will be useful to answer this question. In
addition, mixing experiments with cells from healthy and ure-
mic individuals should help to investigate whether altered
monocyte reactivity contributes to the observed abnormality.
The most striking difference between patients on hemodialysis
and normals was observed when T-B cell collaboration for the
generation of immunoglobulin was examined. Thus, upon stim-
ulation with PWM, PBL from healthy individuals produced up
to 12 times more IgG in vitro than did uremic PBL. All patients
except one produced less than 500 ng IgG/105 PBL. The latter
was a 28—year—old male treated with hemodialysis for seven
years. His primary kidney disease was Alport's syndrome. B
lymphocytes from this patient produced IgG to the same extent
as did B cells from normal controls. Excluding this patient, the
difference between patients and healthy individuals becomes
even more marked under the experimental conditions em-
ployed. Since the production of tgG requires a complex series
of cellular interactions involving T cells, B cells, and
monocytes, defects could exist in any of these populations.
More detailed studies are underway to investigate the function
of isolated lymphocyte and monocyte populations in this sys-
tem. Given that these cells express their activities in the
immune response mainly by providing soluble mediators (IL-I,
IL-2, B cell differentiation factor) which serve as essential
signals in T and B cell activation, and the availability of pure
sources of such lymphokines, these studies may in the future
provide clues to circumvent, in vivo, the acquired im-
munodeficiency of the uremic state.
Acknowledgment
The monoclonal anti-T3 antibody used in this study was provided by
Dr. E.L. Reinherz, Boston, Massachusetts, U.S.A.
Reprint requests to Professor Dr. H. KOhler, I. Medizinische Klinik
und Poliklinik, Joh. Gutenberg—Universitat, Langenbeckstr. I, D-6500
Mainz, Federal Republic of Germany
References
1. ANDREW OT, SCHOENFELD PY, HOPEWELL PC, HUMPHREYS MH:
Tuberculosis in patients with end—stage renal disease. Am J Med
68:59—65, 1980
2. CAPPEL R, VAN BEERS D, LIESNARD C, DRATWA M: Impaired
humoral and cell—mediated immune responses in dialyzed patients
after influenza vaccination. Nephron 33:21—25, 1983
3. Cosso FG, GIEBINK GS, THAN LE C, SCHIFFMAN G: Pneumococ-
cal vaccination in patients with chronic renal disease and renal
allograft recipients. Kidney mt 20:254—258, 1981
4. ORTBALS DW, MARKS ES, LIEBHABER H: Influenza immunization
in patients with chronic renal disease. JAMA 239:2562—2565, 1978
5. RUTSKY EA, ROSTAND SG: Mycobacteriosis in patients with
chronic renal failure. Arch Intern Med 140:57—61, 1980
6. SELROOS 0, PASTERNACK A, VIROLAINEN M: Skin test sensitivity
and antigen—induced lymphocyte transformation in uremia. Clin
Exp Immunol 14:365—370, 1973
7. Dossismir H: Immune system in uremia. Nephron 17:409—414,
1976
8. GOLDBLUM SE, VAN Es DE, REED WP: Serum inhibitor of CS
50
40
30
20
10
E3
.
.
S
.
S
.I
$
.
..
S
.
I
S
.4.
1214 Kurz et a!
fragment—mediated polymorphonuclear leukocyte chemotaxis as-
sociated with chronic hemodialysis. J C/in Invest 64:255—264, 1979
9. RASKA K, MORRISON AB, RASKOVA J: Humoral inhibitors of the
immune response in uremia: Ill. The immunosuppressive factor of
uremic rat serum is a very low density lipoprotein. Lab Invest
42:636—642, 1980
10. CHARPENTIER B, LANG PH, MARTIN B, NOURY J, MATHIEU D,
FRIES D: Depressed polymorphonuclear leukocyte functions asso-
ciated with normal cytotoxic functions of T and natural killer cells
during chronic hemodialysis. C/in Nephrol 19:288—294, 1983
11. MILLER TE, STEWART E: Host immune status in uremia. I.
Cell—mediated immune mechanisms. Clin Exp Immunol
41:115—122, 1980
12. STEWART E, MILLER TE: Host immune status in uraemia. 11.
Serum factors and lymphocyte transformation. C!in Exp Immunol
41:123—129, 1980
13. NAKHLA LS, GOGGIN MJ: Lymphocyte transformation in chronic
renal failure. Immunology 24:229—235, 1973
14. QUADRACCI Li, RINGDEN 0, KRZYMANSKI M: The effect of uremia
and transplantation on lymphocyte subpopulations. Kidney fat
10:179—184, 1976
15. MEUER SC, HUSSEY RE, PENTA AC, FITZGERALD KA, STADLER
BM, SCHLOSSMAN SF, REINHERZ EL: Cellular origin of Interleukin
2 (IL 2) in man: Evidence for stimulus—restricted IL 2 production
by T4* and T8 lymphocytes. J Immunol 129:1076—1079, 1982
16. REINHERZ EL, M0RIM0T0 C, PENTA AC, SCHLOSSMAN SF: Reg-
ulation of B cell immunoglobulin secretion by functional subsets of
T lymphocytes in man. Eur J Immuno! 10:570—572, 1980
17. REINHERZ EL, KUNG PC, GOLDSTEIN G, SCIILOSSMAN SF: Sepa-
ration of functional subsets of human T cells by a monoclonal
antibody. Proc Nat! Acad Sci 76:4061—4065, 1979
18. REINHERZ EL, KUNG PC, GOLDSTEIN G, SCHLOSSMAN SF: Fur-
ther characterization of the human inducer T cell subset defined by
monoclonal antibody. J Immuno! 123:2894—2896, 1979
19. GILLIs 5, FERM MM, Ou W, SMITH KA: T cell growth factor:
Parameters of production and a quantitative microassay for activ-
ity. J Immunol 120:2027—2032, 1978
20. LAWRENCE HS: Uremia—Nature's immunosuppressive device.
Ann Intern Med 62:166—170, 1965
21. KOHLER H, ARNOLD W, RENSCHIN G, DORMEYER HH, MEYER
ZUM BUSCHENFELDE KH: Active hepatitis B vaccination of dialy-
sis patients and medical staff. Kidney In! 25:124—128, 1984
22. MEZZANO 5, PESCE A, PETERS T, POLLAK yE, REED R, MICHAEL
0: Antibody production and antigenic specific suppression to
bovine serum albumin in uremic rats. C/in Exp Immuno!
48:111—117, 1982
23. DE GA5T GC, HOUWEN B, VAN DER HEM OK, THE TH: T-
lymphocyte number and function and the course of hepatitis B in
hemodialysis patients. Infect Immunity 14:1138—1143, 1976
24. LORTAN JE, KIEPIELA PH, COOVADIA HM, SEEDAT YK: Suppres-
sor cells assayed by numerical and functional tests in chronic renal
failure. Kidney Int 22:192—197, 1982
25. NEWBERRY WM, SANFORD iP: Defective cellular immunity in renal
failure: Depression of reactivity of lymphocytes to phytohemag-
glutinin by renal failure serum. J C/in Invest 50:1262—1271, 1971
26. RASKOVA J, GHOBRIAL I, SHEA SM, EISINGER RP, RASKA K:
Suppressor cells in end—stage renal disease. Functional assays and
monoclonal antibody analysis. Am J Med 76:847—853, 1984
